Cloverleaf Bio - About the company
Cloverleaf Bio is a seed company based in New Haven (United States), founded in 2023. It operates as a Developer of RNA-based therapeutics for cancer treatment. Cloverleaf Bio has raised $47.8M in funding. The company has 3350 active competitors, including 1137 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Key Metrics
Founded Year
2023
Location
New Haven, United States
Stage
Seed
Total Funding
$47.8M in 2 rounds
Latest Funding Round
Investors
Ranked
3895th among 3980 competitors
Similar Companies
Sign up to download Cloverleaf Bio's company profile
Cloverleaf Bio's funding and investors
Cloverleaf Bio has raised a total funding of $47.8M over 2 rounds. Its first funding round was on Jun 23, 2025. Its latest funding round was a Seed round on Aug 24, 2026 for $*****. 7 investors participated in its latest round. Cloverleaf Bio has 1 institutional investor.
Here is the list of recent funding rounds of Cloverleaf Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 24, 2026 | 2340876 | Seed | 7692730 | 7941426 | 3192302 | 6223589 |
Jun 23, 2025 | 2723011 | Grant (prize money) | 1112992 | 2732897 | 9629667 |
Access funding benchmarks and valuations. Sign up today!View details of Cloverleaf Bio's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cloverleaf Bio's Competitors and alternates
Top competitors of Cloverleaf Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Cloverleaf Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
3895th | Cloverleaf Bio 2023, New Haven (United States), Seed | Developer of RNA-based therapeutics for cancer treatment | $47.8M | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Cloverleaf Bio's competitors? Click here to see the top ones
Cloverleaf Bio's Investments and acquisitions
Cloverleaf Bio has made no investments or acquisitions yet.
Reports related to Cloverleaf Bio
Here is the latest report on Cloverleaf Bio's sector:
News related to Cloverleaf Bio
Media has covered Cloverleaf Bio for 1 event in last 1 year.
•
4BIO Capital Leads $33 Million Seed Financing for Cloverleaf Bio Advancing RNA-Based Cancer TherapeuticsGlobeNewswire•Sep 08, 2026•Cloverleaf Bio, 4Bio Capital, Lilly, Boehringer Ingelheim Venture Fund and 2 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Cloverleaf Bio
Explore our recently published companies
- Vu Huy Hai - United States based, Unfunded company
- Summary of the Internet - Unfunded company
- Techedout - Unfunded company
- Lindsay B - Maplewood based, Unfunded company
- Tessa Herres - Walla Walla based, Unfunded company
- Edge Course - 2020 founded, Unfunded company
